Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Burlingame, USA
866 Malcolm Road
Suite 100
Burlingame, CA, 94010
USA

Funding

TOTAL $54M
FUNDING TOTAL $54M
Series A, 1/2007
Kleiner Perkins Caufield & Byers
$7.53M
Grant, 8/2007
$9M
Series B, 1/2010
SV Life Sciences
Kleiner Perkins Caufield & Byers
$25M
Series B, 4/2010
SV Life Sciences
Kleiner Perkins Caufield & Byers
$12.5M
DEBT TOTAL $750k
Debt, 10/2010
$750k

Tags

Juvaris BioTherapeutics

Juvaris BioTherapeutics, Inc. is developing adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer.

The Company’s platform technology induces profound immunostimulation via cationic lipid-DNA (non-coding) complexes (CLDC). The Company’s lead product candidate, JVRS-100, stimulates adaptive and innate immune responses at levels many fold higher than other drugs in its class. JVRS-100 is in clinical development as a vaccine adjuvant and an immunotherapeutic.

Recent Milestones

Videos

Screenshots

Juvaris BioTherapeutics screenshot
Above: Juvaris BioTherapeutics
Uploaded: 7/24/09

Sources

  1. Cancer vaccine developer Juvaris raises $7.53M, led by Kleiner Perkins (venturebeat.com) [edit]
  2. Vaccine maker Juvaris Bio gets $9M government grant (venturebeat.com) [edit]
  3. Juvaris BioTherapeutics Completes Second Close on $25M Series B Financing (finsmes.com) [edit]
  4. Juvaris BioTherapeutics, Inc.: Series B $12.5M (onbiovc.com) [edit]
  5. SEC (sec.gov) [edit]
Edit This Page
Last Edited 1/21/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy